A clinical stage biopharmaceutical company focused on developing therapeutics for autoimmune-driven inflammatory diseases
Eliem Therapeutics, following the close of the acquisition of Tenet Medicines, will be focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.
Our Pipeline
Budoprutug, an anti-CD19 mAb, is designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. This reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as SLE, ITP and MN. In a Phase 1b clinical trial of budoprutug in MN, 3 out of 5 (or 60%) of patients that received four doses of budoprutug achieved a complete remission of proteinuria, a primary symptom of MN.
In SLE, one of budoprutug’s lead indications, the underlying pathology involves production of autoantibodies by autoreactive B cells that contribute to inflammation and tissue damage. Because budoprutug is designed to target and deplete CD19-expressing B cells known to produce autoantibodies, the Company believes budoprutug has the potential to treat SLE.
In ITP, the Company believes targeting plasmablasts and plasma cells is likely to decrease the production of autoantibodies, increase platelet count and ameliorate disease. B cell depletion with anti-CD20 targeting mAbs, has demonstrated efficacy in some patients with ITP based on in clinical trials conducted by third parties. For those patients who do not respond to anti-CD20 therapy, the Company believes an anti-CD19 approach, such as budoprutug, may have the ability to further deplete pathogenic CD20-/CD19+ cells.
Our Experienced Team
Leadership Team
Board of Directors
Aoife Brennan, M.B., Ch.B.
President and Chief Executive Officer
Aoife Brennan, M.B., Ch.B.
President and Chief Executive Officer
Aoife brings to Eliem over 20 years of experience leading drug development organizations across a range of stages and therapeutic areas having most recently served as the President and Chief Executive Officer of Synlogic, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology. In that role, she led the organization from early-stage private company to a late-phase public company with internal GMP manufacturing capabilities, pioneering new regulatory pathways for bacterial therapeutics. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc., where she led the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as other early-stage programs. She served as a director of Synlogic from October 2018 to March 2024, as a director of Ra Pharmaceuticals, Inc. from Sept 2018 through its acquisition in April 2020 and currently serves as a director of Fibrogen Inc., Cerevance, LLC and Xilio Therapeutics. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and completed her post-graduate training in internal medicine, endocrinology and metabolism at the Royal College of Physicians in Ireland. She also completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Jan Hillson, M.D.
Senior Clinical Advisor
Jan Hillson, M.D.
Senior Clinical Advisor
Jan is a rheumatologist and clinical immunologist with 20 years of experience in academic research, patient care and teaching, and more than 15 years of experience in the biotech industry spanning translational, preclinical, early and late clinical development. Prior to Eliem, Dr. Hillson was a Partner at Cascadia Drug Development Group providing strategic advisory support, including indication prioritization, investment opportunity diligence, and planning and oversight of therapeutic development with a focus in immunology. Dr. Hillson’s experience in the biotechnology industry includes senior clinical development and leadership roles at ZymoGenetics (acquired by Bristol Myers Squibb), Momenta (acquired by Johnson & Johnson), Chemocentryx (acquired by Amgen), Alpine Immune Sciences, and Provention Bio (acquired by Sanofi), where she was responsible for the design and execution of clinical development plans and trials for multiple therapeutic candidates in autoimmune diseases and immunovirology. Dr. Hillson is currently serving on the Board of Directors for Eledon Pharmaceuticals. Dr. Hillson received her M.D. from Stanford School of Medicine, an M.S. from the California Institute of Technology, an M.S. in Marine Chemistry from Scripps Institute of Oceanography, and a B.S. from Michigan State University.
Brett Kaplan, M.D.
Chief Operating Officer
Brett Kaplan, M.D.
Chief Operating Officer
Brett brings over 20 years of finance and operations leadership in biotechnology and investment banking. Before joining Eliem, Dr. Kaplan served as President, Chief Financial and Corporate Development Officer at Chroma Medicine Inc., where he raised approximately $250 million to fund the research and development of epigenetic editors, a new class of genomic medicines. Prior to Chroma, Dr. Kaplan was the Chief Financial Officer of Prevail Therapeutics, which was acquired by Eli Lilly and Company for $940 million. At Evercore Partners, Dr. Kaplan was a Managing Director, Investment Banking advising on strategic and financing transactions. Dr. Kaplan has held other corporate development and strategy positions at Cubist Pharmaceuticals, a pharmaceutical company acquired by Merck & Co., Inc., Biopure Corporation, and Eli Lilly. Dr. Kaplan is currently a director of Myeloid Therapeutics, Inc. and also served as a director of Compass Therapeutics, Inc. Dr. Kaplan holds an MBBCh. and an M.B.A. from the University of Witwatersrand.
Emily Pimblett
Chief Accounting Officer
Emily Pimblett
Chief Accounting Officer
Emily has served as the Company’s Vice President of Accounting since March 2021 and its Chief Accounting Officer since February 2023. From March 2019 to March 2021, Ms. Pimblett served as Controller at DomainTools, and prior to that she served as Controller at Avvo from July 2017 to March 2019. Previously, Ms. Pimblett spent 9 years in various roles at PricewaterhouseCoopers. Ms. Pimblett holds a B.A. in Business Administration, a Masters in Professional Accounting from the University of Washington, and is a licensed Certified Public Accountant in Washington.
Nishi Rampal, M.D.
Senior Vice President, Clinical Development
Nishi Rampal, M.D.
Senior Vice President, Clinical Development
Nishi brings over 10 years of extensive experience in the pharmaceutical and biotechnology industries with a track record of leadership in rare disease drug development, spanning neurology, rheumatology, dermatology, and hematology. Over the course of her career in industry, she has led programs resulting in successfully global approvals including UPLINZA® (inebilizumab-cdon), a groundbreaking treatment for neuromyelitis optica spectrum disorder and ULTOMIRIS (ravulizumab-cwvz) a treatment for myasthenia gravis. Prior to Eliem, Dr. Rampal was the Executive Director Clinical Development at Horizon Therapeutics (acquired by Amgen, Inc. for $27.8 billion in October 2023), where she was the global lead on the development and strategy for UPLINZA. Prior to Amgen, Dr. Rampal was a Medical Director Clinical Development at Alexion Pharmaceuticals (acquired by AstraZeneca for $39 billion in December 2021). While at Alexion, Dr. Rampal worked on the global pivotal Phase 3 trial for ravulizumab (Ultomiris), CHAMPION® developed for myasthenia gravis. Dr Rampal completed her neurology residency at the Yale School of Medicine and her neurophysiology and epilepsy fellowship at Columbia University, and is double board certified with past academic appointments at Yale University, Columbia University, and Mount Sinai Icahn Schools of Medicine.
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew is a Co-Founder of Eliem Therapeutics and Chairman of the Board of Directors. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a bachelor of science in mechanical engineering from Princeton University, a doctorate in biomedical engineering from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.
Aoife Brennan, M.B., Ch.B.
Aoife Brennan, M.B., Ch.B.
Aoife brings to Eliem over 20 years of experience leading drug development organizations across a range of stages and therapeutic areas having most recently served as the President and Chief Executive Officer of Synlogic, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology. In that role, she led the organization from early-stage private company to a late-phase public company with internal GMP manufacturing capabilities, pioneering new regulatory pathways for bacterial therapeutics. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc., where she led the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as other early-stage programs. She served as a director of Synlogic from October 2018 to March 2024, as a director of Ra Pharmaceuticals, Inc. from Sept 2018 through its acquisition in April 2020 and currently serves as a director of Fibrogen Inc., Cerevance, LLC and Xilio Therapeutics. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and completed her post-graduate training in internal medicine, endocrinology and metabolism at the Royal College of Physicians in Ireland. She also completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Judith Dunn, Ph.D.
Judith Dunn, Ph.D.
Judy is the President and Head of R&D at Fulcrum Therapeutics. Prior to this role, Judy was an Entrepreneur-in-Residence at Atlas Venture, where she focused on new company creation. Previously, Judy served as Vice President and Global Head of Clinical Development at Roche in Basel, Switzerland, and Head of the Roche Innovation Center in NYC. She has held leadership positions in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor. Judy is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. She has also served as a scientific advisor to the Tri-Institutional Therapeutics Discovery Institute and as a board member of the Partnership for NY Fund.
Liam Ratcliffe, M.D., Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Liam is the head of Access Biotechnology, the strategic investment arm specializing in therapeutic platforms and products at Access Industries. Prior to his work at Access Industries, he was Managing Director at New Leaf Venture Partners, where he concentrated on biopharmaceutical investing. Prior to joining New Leaf in 2008, Liam served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Midwest region (based in Ann Arbor, Mich.) and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. He received his medical degree and doctorate in immunology from the University of Cape Town and his master of business administration from the University of Michigan. He completed his internal medicine training and fellowship in immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Adam Rosenberg
Adam Rosenberg
Adam is CEO of Aliada Therapeutics and currently serves on other private company boards (including Sionna Therapeutics and is Chair of Ambagon Therapeutics). Adam was most recently a Venture Partner at Carnot Pharma (RA Ventures). Adam was previously President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.
Simon Tate
Simon Tate
Simon is a Managing Director at Intermediate Capital Group (ICG) and has 30 years of experience in R&D. He has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, he led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.
Stephen Thomas, Ph.D.
Stephen Thomas, Ph.D.
Stephen, previously CEO and co-founder of Tenet Medicines, Inc., brings broad experience in drug discovery and development, business development, and capital raises. Prior to Tenet, Mr. Thomas served as CSO of ValenzaBio, Inc., a clinical-stage biotechnology company, up until its acquisition by ACELYRIN, INC. At ValenzaBio, Mr. Thomas led the successful development of three antibody pipeline programs in I&I from preclinical to clinical proof-of-concept, including the anti-IGF-1R monoclonal antibody lonigutamab, and served a pivotal role in overall corporate strategy and fundraisings. Prior to ValenzaBio, Mr. Thomas was CSO and co-founder of Ichorion Therapeutics, Inc., where he built and advanced a pipeline of therapies for rare pediatric diseases up until its acquisition by Cerecor, Inc. Mr. Thomas holds a Ph.D. in organic synthesis and chemical biology from Columbia University, where he was a Bristol-Myers Squibb Fellow and NSF Predoctoral Fellow, and was previously an Amgen Scholar.
News
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the
Load More
11/12/2024
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls
11/11/2024
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the
10/31/2024
WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below. Guggenheim Securities Healthcare Innovation Conference Format: Fireside chat and
10/15/2024
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune
10/11/2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024. Poster Presentation A Phase 1b Single Arm Open-Label Study
10/04/2024
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024. About Climb Bio, Inc.
10/03/2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on
10/02/2024
Name change to “Climb Bio” marks the Company’s transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol “CLYM” effective October 3rd WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc.
09/11/2024
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc . (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
08/26/2024
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc . (Nasdaq: ELYM), announced today the appointments of Brett Kaplan, M.D., as
08/14/2024
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents
06/28/2024
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc . (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock
06/27/2024
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations into 2027, to
04/11/2024
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life
07/20/2023
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further
05/11/2023
Presented initial preclinical data from ETX-123, Eliem’s lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, United Kingdom, May
03/06/2023
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) — Eliem
02/09/2023
Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment Implementing corporate reorganization to extend cash runway into 2027 SEATTLE and
11/30/2022
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other
11/14/2022
Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025
11/08/2022
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of
10/05/2022
Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1 pharmacokinetic trial that are consistent with prior clinical trials Progressing into IND-enabling
08/15/2022
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused
08/02/2022
Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc. (Nasdaq: ELYM), a clinical-stage biotechnology
07/18/2022
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, July 18, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc.
07/07/2022
SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
06/27/2022
Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing
05/16/2022
SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
04/25/2022
Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular pain (LSRP) has been fully enrolled with topline data anticipated in the third quarter of 2022
04/05/2022
SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
03/21/2022
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
03/07/2022
Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of ETX-155 in subjects with photosensitive epilepsy to be presented in 1H 2022 Submitted Investigational
03/06/2022
By Bob Azelby
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
02/11/2022
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
02/07/2022
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
01/18/2022
ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD) Patient dosing underway for ETX-155 Phase 1b
11/04/2021
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the
08/13/2021
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central
08/10/2021
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the
05/24/2021
Advances two clinical programs through topline data across four indications Progresses two preclinical programs to potential lead candidate selection Brings total funding since inception to $140 million SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a
03/25/2021
SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ — Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019.
Careers
We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.
We’d love to connect.
Contact Us
MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
PMB #117
2801 Centerville Road, 1st Floor
Wilmington, DE 19808-1609
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT
PMB #117
2801 Centerville Road, 1st Floor
Wilmington, DE 19808-1609
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT